Screening of mortality in transplant patients using an assay for immune function.

[1]  S. Alexander,et al.  Rejection of the kidney allograft. , 2010, The New England journal of medicine.

[2]  Y. S. Kim,et al.  Increased Incidence of Colorectal Malignancies in Renal Transplant Recipients: A Case Control Study , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  J. Fung,et al.  Measurement of CD4+ T‐cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation , 2010, Clinical transplantation.

[4]  A. Battler,et al.  Individualized Immune Monitoring of Cardiac Transplant Recipients by Noninvasive Longitudinal Cellular Immunity Tests , 2010, Transplantation.

[5]  N. Xu,et al.  Immune Cell Functional Assay in Monitoring of Adult Liver Transplantation Recipients With Infection , 2010, Transplantation.

[6]  C. Pietrangeli,et al.  Delayed Onset CMV Disease in Solid Organ Transplant Recipients , 2009 .

[7]  D. Pakstis,et al.  Experience With Immune Monitoring in Lung Transplant Recipients: Correlation of Low Immune Function With Infection , 2009, Transplantation.

[8]  V. Krishnamurthi.  Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study , 2008 .

[9]  M. Pascual,et al.  Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. , 2008, Transplant immunology.

[10]  W. Vigneswaran,et al.  Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  H. Meier‐Kriesche,et al.  Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  B. Maes,et al.  Risk Factors for Cardiovascular Events After Successful Renal Transplantation , 2005, Transplantation.

[13]  L. Hilbrands,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2008, The New England journal of medicine.

[14]  A. Yussim,et al.  Preceeding the rejection: in search for a comprehensive post-transplant immune monitoring platform. , 2007, Transplant immunology.

[15]  E. Reed,et al.  Assessing Relative Risks of Infection and Rejection: A Meta-analysis using an Immune Function Assay , 2006, Transplantation.

[16]  A. Rodriguez-trinidad,et al.  Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. , 2006, Transplantation proceedings.

[17]  M. Kramer,et al.  Development of Malignancy Following Lung Transplantation , 2006, Transplantation.

[18]  D. Brennan,et al.  The Incidence and Costs of Sepsis and Pneumonia Before and After Renal Transplantation in the United States , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  E. Woodle,et al.  Malignancy after Transplantation , 2005, Transplantation.

[20]  A. Webster,et al.  Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data , 2005, BMJ : British Medical Journal.

[21]  K. Budde,et al.  Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation , 2005, Transplantation.

[22]  R. Arons,et al.  The Burden of Acute Renal Failure in Nonrenal Solid Organ Transplantation , 2004, Transplantation.

[23]  C. Troppmann,et al.  Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study , 2003, Transplantation.

[24]  A. Heredia,et al.  Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management , 2003, Clinical transplantation.

[25]  T. Theruvath,et al.  Strategies to improve long-term outcomes after renal transplantation. , 2002, The New England journal of medicine.

[26]  S. E. Miller,et al.  Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. , 1999, Transplantation.

[27]  M. Gershwin,et al.  Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. , 1999, Transplant Immunology.

[28]  P. Vereerstraeten,et al.  LATE MORTALITY AND MORBIDITY FIVE TO EIGHTEEN YEARS AFTER KIDNEY TRANSPLANTATION , 1988, Transplantation.

[29]  T. Strom,et al.  Late Mortality and Morbidity in Recipients of Long-Term Renal Allografts , 1983 .